ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 81.46% ano a ano.
Alto Crescimento de Lucro
O lucro líquido da empresa lidera o setor, com o lucro anual mais recente totalizando US$ 883.37M.
Virada para Lucro
O desempenho da empresa passou a ser positivo, com lucro líquido anual mais recente de US$ .
Avaliação Justa
O PE mais recente da empresa é 20.19, em uma faixa percentil média de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 23.15M ações, um aumento de 0.25% em relação ao trimestre anterior.
Mantido por John Hussman
O Super Investidor John Hussman possui 49.41K ações desta empresa.